Welcome to our dedicated page for Ispecimen news (Ticker: ISPC), a resource for investors and traders seeking the latest updates and insights on Ispecimen stock.
iSpecimen Inc. reports developments tied to its online marketplace for human biospecimens, which connects life science researchers with a network of healthcare specimen providers. Company updates cover biospecimen sourcing for research projects, supplier-network responsiveness, direct-to-customer shipping, and marketplace technology used to match customer requests with available inventory.
Recurring news themes include AI-assisted inventory matching, SalesStack marketplace integration, respiratory and other specimen procurement, international sourcing relationships, and capital-structure actions such as the completed reverse stock split of ISPC common stock.
iSpecimen (Nasdaq: ISPC) priced a private placement for aggregate gross proceeds of approximately $2.5 million, issuing 488,281 common shares at $5.12 per share and offering pre-funded warrants at $5.1199 where exercisable for one share at $0.0001 per share.
The company intends to use net proceeds for working capital, including up to $900,000 for marketing. The offering is expected to close on or about May 11, 2026, is capped at 19.99% of outstanding shares pending stockholder approval, and E.F. Hutton serves as placement agent.
iSpecimen (NASDAQ: ISPC) will effect a 1-for-40 reverse stock split effective 4:30 p.m. ET on April 27, 2026, with split-adjusted trading beginning on April 28, 2026. The company will retain the ticker ISPC and receive new CUSIP 45032V306.
Outstanding shares will be reduced from 52,639,796 to 1,316,032. Options, warrants, RSUs and plan reserves will be proportionally adjusted; fractional shares will be rounded up to whole shares at the participant level. The company said the split is intended to raise the per-share trading price and help satisfy Nasdaq minimum bid requirements.
iSpecimen (NASDAQ: ISPC) implemented a direct shipping model that cuts human biospecimen transit times by ~70–85% and enables domestic deliveries in as little as 1–2 days.
The change reduces reliance on central hubs, lowers shipping handoffs and costs, and pairs with strengthened European and Eastern European supplier partnerships to improve access to rare specimens and consistency for international requests.
iSpecimen (NASDAQ: ISPC) reported a rapid procurement milestone for influenza research on March 16, 2026, collecting approximately 500 influenza swab samples over several weeks to support a customer project.
The company also maintained supply of cerebrospinal fluid (CSF), and noted rising demand for FFPE and fresh frozen tissue. Customer feedback praised specimen quality and documentation, with one customer indicating intent to credit iSpecimen as the sample source in publications.
iSpecimen (NASDAQ: ISPC) on March 12, 2026 launched an AI-powered Inventory Agent embedded in its redesigned marketplace to accelerate biospecimen request review and matching. The LLM-driven agent extracts criteria from plain-language requests, ranks potential matches, and aims to reduce manual review while retaining expert oversight.
The company plans additional AI features for regulatory monitoring, workflow automation, and lead qualification to streamline biospecimen sourcing.
iSpecimen (NASDAQ: ISPC) announced completion of Milestone 2: System Integration and Marketplace Activation on February 6, 2026, delivering a live SalesStack production marketplace. Key achievements include end-to-end system integration, full legacy data migration, core feature enablement, AI-assisted matching, and launch of a production site at https://mp.ispecimen.com.
Company says the update enables operational continuity, cost reductions from legacy sunset, improved scalability and performance, and a foundation for supplier onboarding, pricing automation, and broader rollouts ahead of Milestone 3.
iSpecimen (NASDAQ: ISPC) reported a rapid procurement milestone on February 6, 2026, collecting 500 influenza swab samples in a few weeks to support a customer research project. The company also reports steady supply of cerebrospinal fluid (CSF) and rising demand for FFPE and fresh frozen tissue specimens. Customer feedback praised specimen quality and documentation for a 20-sample urine shipment and indicated intent to cite iSpecimen as the sample source in publications, underlining continued customer engagement and confidence.
iSpecimen (Nasdaq: ISPC) announced a private placement expected to raise approximately $5.5 million in gross proceeds through the issuance of 6,875 shares of newly designated Series C Convertible Preferred Stock at $800 per share.
Each preferred share has a $1,000 stated value and converts into common stock at a conversion price equal to 85% of the closing price of common stock on the trading day before each conversion date. The company intends to use net proceeds for marketing, working capital, and general corporate purposes. Closing is expected on or about December 31, 2025, subject to customary conditions. E.F. Hutton is the exclusive placement agent. The securities are offered in a private placement to accredited investors and the company agreed to file registration statements covering resale of conversion shares.
iSpecimen (NASDAQ: ISPC) has provided an update on its strategic initiative to integrate digital assets into its business model. The company is pursuing the development of a $200 million corporate treasury reserve based on the Solana blockchain ecosystem. Since its August announcement, ISPC has received approaches from several cryptocurrency companies presenting opportunities in tokenized real-world assets and highly ranked cryptocurrencies.
Under CEO Robert Lim's leadership, iSpecimen plans to establish a SOL-based treasury program to diversify its balance sheet and support long-term growth. The company intends to implement a "buy and HODL" strategy, including purchasing Locked SOL at a discount and utilizing staking mechanisms to generate yields. The program will be funded through future capital raises and will include the acquisition of both locked and unlocked SOL through reputable cryptocurrency institutions.
iSpecimen (NASDAQ: ISPC), a human biospecimens marketplace, has completed Milestone 1 of its digital transformation program with Salestack Solutions. The milestone involves implementing Salestack's cloud-native platform to modernize the iSpecimen Marketplace® infrastructure.
Key improvements include Infrastructure-as-Code (IaC), unified storage and workflows, and a future-ready foundation supporting multi-cloud deployment. The upgrade provides automated security, improved reliability, and faster development cycles. This completion sets the stage for Milestone 2 (Integration), which will focus on connecting all business operations to the Salestack platform.